<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539340</url>
  </required_header>
  <id_info>
    <org_study_id>IDB-MPS-I</org_study_id>
    <nct_id>NCT04539340</nct_id>
  </id_info>
  <brief_title>A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers</brief_title>
  <official_title>An Open-label Multi-cohort Dose-escalation Study to Evaluate the Tolerance, Safety, and Pharmacokinetics of GNR-055 (GENERIUM JSC, Russia) in Healthy Volunteers With a Single Intravenous Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO GENERIUM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO GENERIUM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the&#xD;
      tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GNR-055 is intended for ERT in patient with Mucopolysaccharidosis type II (MPS II), or Hunter&#xD;
      syndrome. MPS II is a lysosomal storage disease with an X-linked recessive inheritance type,&#xD;
      which is characterized by a decrease in the activity of the lysosomal enzyme&#xD;
      iduronate-2-sulfatase (I2S), caused by a mutation in the IDS gene. Enzyme deficiency leads to&#xD;
      the accumulation of glycosaminoglycans (GAG) in lysosomes, mainly fractions of heparan and&#xD;
      dermatan sulfates. Because of the insufficient activity of iduronate sulfatase participating&#xD;
      in the first stage of catabolism of GAG, they accumulate in lysosomes of almost all types of&#xD;
      cells of various tissues and organs. The disease is manifested by growth retardation, damage&#xD;
      of many organs and systems, severe deformations of bones and joints, gross facial features,&#xD;
      pathology of the respiratory and cardiovascular systems, damage to parenchymal organs&#xD;
      (hepatosplenomegaly), and hearing impairment. A severe form of the disease occurs with the&#xD;
      involvement of the nervous system in the pathological process, including mental retardation,&#xD;
      behavior anomalies, and impaired motor function.&#xD;
&#xD;
      GNR 055 is a modified enzyme iduronate-2-sulfatase capable of penetrating the blood-brain&#xD;
      barrier and thus it is expected to prevent neurodegenerative consequences and the development&#xD;
      of cognitive deficit in the future that will allow achieving a significant improvement in the&#xD;
      life quality and expectancy of patients with MPS II&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Actual">September 8, 2020</completion_date>
  <primary_completion_date type="Actual">September 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Day 7 ± 1</time_frame>
    <description>Adverse events, Laboratory tests, Vital signs, Physical examination, 12-lead electrocardiogram, Allergic associated reaction, Infusion associated reaction, Antidrug antibody.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum pharmacokinetic parameters of GNR-055</measure>
    <time_frame>Day 2</time_frame>
    <description>Serum concentration GNR-055, Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax - Maximum Serum Concentration</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC - Area Under the Curve</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Т1/2 - Half-life</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel - Elimination rate constant</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT - Mean residence time</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl - Clearance</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz - volume of distribution</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Mucopolysaccharidosis Type II</condition>
  <condition>Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>Cohort 1 GNR-055 (0.3 mg/kg)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-055 (0.3 mg/kg) Single intravenous administration GNR-055</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 GNR-055 (0.5 mg/kg)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-055 (0.5 mg/kg) Single intravenous administration GNR-055</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 GNR-055 (1 mg/kg)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-055 (1 mg/kg) Single intravenous administration GNR-055</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 GNR-055 ( 2 mg/kg)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-055 ( 2 mg/kg) Single intravenous administration GNR-055</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 GNR-055 (3 mg/kg)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-055 (3 mg/kg) Single intravenous administration GNR-055</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-055</intervention_name>
    <description>Single intravenous administration</description>
    <arm_group_label>Cohort 1 GNR-055 (0.3 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 2 GNR-055 (0.5 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 3 GNR-055 (1 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 4 GNR-055 ( 2 mg/kg)</arm_group_label>
    <arm_group_label>Cohort 5 GNR-055 (3 mg/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged 18 to 50 years (inclusive) at the time of signing the Informed Consent Form;&#xD;
&#xD;
          -  Body mass index (BMI) 18.5 to 30 kg/m2, body weight of 50 to 90 kg;&#xD;
&#xD;
          -  A verified diagnosis as &quot;healthy&quot; (the diagnosis &quot;healthy&quot; is established on the basis&#xD;
             of a detailed medical history, in the absence of deviations from normal values during&#xD;
             a clinical examination, including measurement of blood pressure, respiratory rate,&#xD;
             heart rate, body temperature, laboratory and instrumental (ECG) examination data);&#xD;
&#xD;
          -  A written informed consent to participate in the study in accordance with applicable&#xD;
             laws in place and compliance with all the procedures and requirements/restrictions&#xD;
             provided for by the study protocol;&#xD;
&#xD;
          -  Consent to use adequate methods of contraception (double barrier method-male or female&#xD;
             (for partners of male research volunteers), condom with spermicide, intrauterine&#xD;
             device (IUD), diaphragm with spermicide, contraceptive sponge, cervical cap with&#xD;
             spermicide).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to idursulfase and/or to the medicinal product excipients;&#xD;
&#xD;
          -  Burdened allergy history;&#xD;
&#xD;
          -  Drug intolerance;&#xD;
&#xD;
          -  History of seizures;&#xD;
&#xD;
          -  Deposit injections or implants use of any other medicinal product three months before&#xD;
             the Screening Visit;&#xD;
&#xD;
          -  An unusual way of living (night working, extreme physical activity);&#xD;
&#xD;
          -  Diarrhea dehydration, vomiting, or other causes within 24 hours before the Screening&#xD;
             Visit;&#xD;
&#xD;
          -  Deviations from the normal values of the clinical, laboratory, and ECG examinations;&#xD;
&#xD;
          -  If there are acute or chronic diseases of the cardiovascular, bronchopulmonary,&#xD;
             nervous, immune, and endocrine systems, diseases of the gastrointestinal tract, liver&#xD;
             and biliary tract, kidney and urinary tract, blood and lymphatic system, a history of&#xD;
             mental illness;&#xD;
&#xD;
          -  Positive results for hepatitis B or C markers, human immunodeficiency virus (HIV), and&#xD;
             syphilis;&#xD;
&#xD;
          -  Acute infectious diseases less than four weeks before the Screening Visit;&#xD;
&#xD;
          -  Regular administration of medicinal products less than two weeks before the Screening&#xD;
             Visit;&#xD;
&#xD;
          -  Systolic blood pressure (SBP) below 100 mm Hg or above 140 mm Hg; diastolic blood&#xD;
             pressure (DBP) below 70 mm Hg or above 90 mm Hg; HR below 60 bpm or above 80 bpm;&#xD;
&#xD;
          -  Blood donation (450 mL or more of blood or plasma) less than three months before the&#xD;
             Screening Visit;&#xD;
&#xD;
          -  Participation in human clinical studies of medicinal products less than three months&#xD;
             before the Screening Visit;&#xD;
&#xD;
          -  Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent&#xD;
             to 0.5 L of beer, 200 mL of dry wine, or 50 mL of strong spirits) OR history of&#xD;
             alcoholism;&#xD;
&#xD;
          -  Alcohol exhale positive test;&#xD;
&#xD;
          -  Drug addiction, toxic substance abuse, a positive urine analysis for potent and&#xD;
             narcotic substances, including cocaine, cannabis, amphetamine, barbiturates,&#xD;
             benzodiazepines, and opioids;&#xD;
&#xD;
          -  Smoking more than 10 cigarettes per day;&#xD;
&#xD;
          -  Other reasons that, in the opinion of the investigator, prevent a volunteer from&#xD;
             participating in the study or cause an unreasonable risk.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>FSAEI HE &quot;I.M. Sechenov First Moscow State Medical University&quot; of the Ministry of Health of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucopolysaccharidosis type II</keyword>
  <keyword>Mucopolysaccharidoses</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Carbohydrate Metabolism, Inborn</keyword>
  <keyword>Metabolism, Inborn</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Neurobehavioral Manifestations</keyword>
  <keyword>Neurologic Manifestations</keyword>
  <keyword>Genetic Diseases, X-Linked</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

